Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) should vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Glass Lewis concluded in its report that “we do not believe there exists persuasive.

Business Wire • Dec 12, 2025

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with respect to the proposed acquisition of the Company by Alcon Inc. (“Alcon”) (NYSE: ALC). In addition, Broadwood released a new presentation explaining why it continues to oppose the proposed transaction, which can be viewed here. Broadwood, which owns 3.

Business Wire • Dec 11, 2025

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement to correct misinformation regarding its robust go-shop process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC). Broadwood Partners, L.P. (“Broadwood”) falsely alleges there was a credible buyer who had a strong interest in acquiri.

Business Wire • Dec 11, 2025

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.

Benzinga • Dec 10, 2025

Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders regarding the closing of STAAR's go-shop period and the revised offer of Alcon Inc. (SIX/NYSE: ALC) to acquire STAAR for $30.75 per share. The text of the letter is as follows: December 10, 2025 De.

Business Wire • Dec 10, 2025

Alcon lifts bid for medical technology firm Staar to $1.6 billion

Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.

Reuters • Dec 9, 2025

Alcon Announces Amended Merger Agreement with STAAR Surgical

GENEVA--(BUSINESS WIRE)--Alcon Announces Amended Merger Agreement with STAAR Surgical.

Business Wire • Dec 9, 2025

Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to oppose the proposed sale of the Company to Alcon and issued the following statement: “STAAR spent months trying to conv.

Business Wire • Dec 9, 2025

STAAR Surgical Announces Expiration of Go-Shop Period

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR's amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m. Eastern Time on December 6, 2025. No proposals were received prior to the expiration. During the go-shop perio.

Business Wire • Dec 8, 2025

Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffirmed its recommendation that shareholders vote “AGAINST” the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC) on the GREEN Proxy Card. Earlier today, the Company announced the completion of the belated, band-aid 30-day go-s.

Business Wire • Dec 8, 2025